Gonadorelin
GnRH / LHRH / Factrel / Lutrepulse
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), identical in structure to the endogenous hypothalamic decapeptide that controls reproductive hormone secretion. When administered in pulsatile fashion, it stimulates the anterior pituitary to release both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is used clinically for diagnostic testing of pituitary function and therapeutically to maintain fertility during testosterone replacement therapy.
作用機序
Synthetic analog of endogenous gonadotropin-releasing hormone (GnRH). Pulsatile administration stimulates FSH and LH release from the anterior pituitary. Continuous administration paradoxically downregulates the HPG axis through receptor desensitization.
研究プロトコル
研究目的のみで使用。医療アドバイスではありません。
Pulsatile protocols use 25-100mcg subcutaneously every 90-120 minutes via pump to mimic natural GnRH pulses. Diagnostic test protocols use a single 100mcg IV dose. Continuous dosing protocols (suppressive) not commonly used with the native peptide.
研究ノート
Clinical Research Status
Gonadorelin has FDA approval as a diagnostic agent (Factrel) for evaluating pituitary gonadotroph function and in pulsatile form (Lutrepulse) for hypothalamic amenorrhea, though the latter formulation has been discontinued. It is increasingly prescribed off-label by TRT clinics as an alternative to HCG for maintaining LH/FSH secretion and testicular function. Current research focuses on its role in preserving spermatogenesis during exogenous testosterone administration.
Key Published Findings
Pulsatile GnRH administration has been demonstrated to restore ovulation in women with hypothalamic amenorrhea with pregnancy rates of 20-30% per cycle. In male patients on TRT, subcutaneous gonadorelin at doses of 100-400 mcg administered two to three times daily can maintain measurable LH and FSH levels. The pulsatile pattern is critical as continuous administration paradoxically suppresses gonadotropin release through receptor downregulation.
Safety Profile
Gonadorelin has an excellent safety profile with minimal systemic side effects when used at appropriate doses. Injection site reactions are the most commonly reported adverse event. Headache, flushing, and abdominal discomfort occur rarely. The main clinical concern is ensuring pulsatile rather than continuous dosing patterns to avoid the paradoxical suppressive effect seen with GnRH agonists.
Comparison to Related Compounds
Unlike HCG which directly stimulates Leydig cells, gonadorelin works upstream by stimulating the pituitary to release endogenous LH and FSH, maintaining more physiological hormonal signaling. Compared to GnRH agonists like leuprolide or triptorelin, gonadorelin at pulsatile doses stimulates rather than suppresses the reproductive axis. It offers a more physiological approach to fertility preservation during TRT but requires more frequent dosing than HCG.
Community Observations
Gonadorelin gained significant popularity after 2020 when compounded HCG became harder to obtain, with many TRT clinics switching patients to gonadorelin protocols. Practitioners note that effective use requires proper dosing frequency (typically twice daily subcutaneous injections) to mimic natural GnRH pulsatility. Some clinicians report that gonadorelin is less reliably effective than HCG for testicular size maintenance, though individual responses vary.
半減期
~2-4 minutes
再構成
Bacteriostatic water (BAC)
保存
乾燥粉末
Refrigerate 2-8C up to 12 months.
再溶解
Refrigerate 2-8C. Use within 14 days.
米国法的状況
また知られる名前
よくある質問
Gonadorelinとは何ですか?
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), identical in structure to the endogenous hypothalamic decapeptide that controls reproductive hormone secretion. When administered in pulsatile fashion, it stimulates the anterior pituitary to release both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is used clinically for diagnostic testing of pituitary function and therapeutically to maintain fertility during testosterone replacement therapy.
Gonadorelinはどのように作用しますか?
Synthetic analog of endogenous gonadotropin-releasing hormone (GnRH). Pulsatile administration stimulates FSH and LH release from the anterior pituitary. Continuous administration paradoxically downregulates the HPG axis through receptor desensitization.
Gonadorelinの米国での規制状況は?
FDA-approved for diagnostic use (Rx only)
Gonadorelinの半減期は?
~2-4 minutes
Gonadorelinの別名は?
GnRH, LHRH, Factrel, Lutrepulse
ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。
完全な免責事項を読む